The Nasdaq Panel has determined to continue the listing of the Company's securities on The Nasdaq Stock Market and is closing this matterFour upcoming milestones expected: data from trials in Suicidal Bipolar Depression and Chronic Pain, NDA filing for IV Ketamine and distribution of shares of HOPE Therapeutics to existing shareholdersRecent unanticipated achievements related to intravenous ketamine and complicated Urinary Tract Infection/pyelonephritisRADNOR, Pa., April 18, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) ("NRx Pharmaceuticals", "NRx", the "Company"), a clinical-stage biopharmaceutical company, today announced that (the "Company") has received confirmation from Nasdaq that they have demonstrated compliance with the Nasdaq bid ...

SINGAPORE, April 17, 2024 /PRNewswire/ -- Canaan Inc. (NASDAQ: CAN) ("Canaan" or the "Company"), a leading high-performance computing solutions provider, today announced the filing of its annual report on Form 20-F for the fiscal year ended December 31, 2023 with the U.S. Securities and Exchange Commission (the "SEC") on April 17, 2024. The annual report on Form 20-F can be accessed on the SEC's website at http://www.sec.gov and on the Company's investor relations website at https://investor.canaan-creative.com/.

Total Revenues Increased 29.8% Year-over-Year for the Fourth Quarter,55.9% Year-over-Year Growth for the Full Year 2023 149 Net New Store Openings During the Fourth Quarter,912 System-Wide Stores at Year-End 2023 18.7 Million Registered Loyalty Members at Year-End,Representing 66.3% Year-over-Year Growth SHANGHAI, China and ...

PRINCETON, N.J., April 18, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) ("Soligenix" or the "Company"), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced the pricing of its public offering of 11,875,000 shares of common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 11,875,000 shares of common stock at a combined public offering price of $0.40 per share and accompanying warrant for aggregate gross proceeds of approximately $4.75 million, before deducting placement agent fees and other offering expenses. The warrants ...